VanEck Associates
AMED

VanEck Associates’s Amedisys AMED Stock Holding History

VanEck Associates’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-938
Closed -$91K – 1424
2022
Q3 		$91K Buy
938
+84
+10% +$10K ﹤0.01% 1190
2022
Q2 		$90K Sell
854
-44
-5% -$5.62K ﹤0.01% 1232
2022
Q1 		$155K Buy
898
+123
+16% +$18.4K ﹤0.01% 1145
2021
Q4 		$125K Buy
775
+93
+14% +$14.9K ﹤0.01% 1199
2021
Q3 		$102K Buy
682
+253
+59% +$52.6K ﹤0.01% 1142
2021
Q2 		$105K Buy
429
+248
+137% +$65.1K ﹤0.01% 1082
2021
Q1 		$48K Buy
+181
New +$51K ﹤0.01% 1084

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VanEck Associates's AMED Position: Q4 2022 in Review

VanEck Associates sold out of Amedisys (AMED) in Q4 2022, closing a stake of 938 shares — an estimated $91K sold.

VanEck Associates first reported a position in AMED in Q1 2021 and held it in 7 quarters. The position peaked at $155K in Q1 2022. 277 funds tracked by Wall St. Rank hold AMED as of Q4 2022.

  • VanEck Associates reported no remaining Amedisys position as of Q4 2022 after selling out during the quarter.
  • VanEck Associates sold 938 Amedisys shares in Q4 2022, an estimated $91K.
  • VanEck Associates first reported a position in Amedisys in Q1 2021 and held it in 7 quarters.
  • VanEck Associates's Amedisys position peaked at $155K in Q1 2022.
  • 277 funds tracked by Wall St. Rank held Amedisys as of Q4 2022.

Based on VanEck Associates's 13F filing for Q4 2022, filed 8 Feb 2023.